EyePoint Pharmaceuticals, Inc. (FRA:PV3B)

EyePoint Pharmaceuticals Statistics

Total Valuation

FRA:PV3B has a market cap or net worth of EUR 1.02 billion. The enterprise value is 860.02 million.

Market Cap	1.02B
Enterprise Value	860.02M

Important Dates

The next estimated earnings date is Monday, March 2, 2026.

Earnings Date	Mar 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	82.79M
Shares Outstanding	n/a
Shares Change (YoY)	+35.36%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	0.83%
Owned by Institutions (%)	60.44%
Float	61.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	28.14
PB Ratio	5.95
P/TBV Ratio	5.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.90
EV / Sales	23.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.72

Financial Position

The company has a current ratio of 7.18, with a Debt / Equity ratio of 0.12.

Current Ratio	7.18
Quick Ratio	6.81
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-15,595.12

Financial Efficiency

Return on equity (ROE) is -98.23% and return on invested capital (ROIC) is -58.65%.

Return on Equity (ROE)	-98.23%
Return on Assets (ROA)	-49.39%
Return on Invested Capital (ROIC)	-58.65%
Return on Capital Employed (ROCE)	-98.52%
Revenue Per Employee	218,700
Profits Per Employee	-1.06M
Employee Count	165
Asset Turnover	0.15
Inventory Turnover	82.88

Taxes

In the past 12 months, FRA:PV3B has paid 155,971 in taxes.

Income Tax	155,971
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +42.80% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+42.80%
50-Day Moving Average	10.86
200-Day Moving Average	8.10
Relative Strength Index (RSI)	62.18
Average Volume (20 Days)	72

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.85

Income Statement

In the last 12 months, FRA:PV3B had revenue of EUR 36.09 million and -175.36 million in losses. Loss per share was -2.56.

Revenue	36.09M
Gross Profit	-137.57M
Operating Income	-186.08M
Pretax Income	-175.21M
Net Income	-175.36M
EBITDA	-184.31M
EBIT	-186.08M
Loss Per Share	-2.56

Balance Sheet

The company has 173.89 million in cash and 19.83 million in debt, giving a net cash position of 154.06 million.

Cash & Cash Equivalents	173.89M
Total Debt	19.83M
Net Cash	154.06M
Net Cash Per Share	n/a
Equity (Book Value)	170.62M
Book Value Per Share	2.45
Working Capital	158.54M

Cash Flow

In the last 12 months, operating cash flow was -179.76 million and capital expenditures -2.28 million, giving a free cash flow of -182.04 million.

Operating Cash Flow	-179.76M
Capital Expenditures	-2.28M
Free Cash Flow	-182.04M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-515.67%
Pretax Margin	-485.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:PV3B does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-35.36%
Shareholder Yield	-35.36%
Earnings Yield	-17.27%
FCF Yield	-17.93%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 9, 2020. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 9, 2020
Split Type	Reverse
Split Ratio	0.1

Scores

FRA:PV3B has an Altman Z-Score of -0.7 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.7
Piotroski F-Score	1